Pharmafile Logo

Google

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Datroway given FDA Priority Review for breast cancer treatment

Approximately 70% of metastatic triple-negative breast cancer patients are ineligible for immunotherapy, creating an unmet medical need

- PMLiVE

Gilead’s Trodelvy plus Keytruda shows positive results in metastatic breast cancer

The combination treatment showed a 35% reduction in the risk of disease progression

- PMLiVE

Lilly announces new study data on Inluriyo in metastatic breast cancer

The five-year survival rate for metastatic breast cancer is 30%

VuuAI and Amiculum

VuuAI and Amiculum partner to transform content engagement in pharma

Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation platform. The collaboration is designed to optimize the deployment of...

Amiculum

- PMLiVE

Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

Inizio

- PMLiVE

Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

The drug treatment is being evaluated in several ongoing phase 3 trials

- PMLiVE

Enhancing Medical Education through Gamification and Innovative Technologies

One innovative approach that has gained traction in recent years is gamification—the integration of game elements such as points, leaderboards, and interactive elements into learning activities. Understanding gamification’s role in...

Impetus Digital

- PMLiVE

Lilly reports survival benefit with Verzenio in high-risk early breast cancer

The findings are based on Lilly’s phase 3 monarchE trial

- PMLiVE

Almirall and Absci expand AI dermatological drug discovery partnership

The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links